Table 3 Safety of Peptide Receptor Radionuclide Therapy in patients with Advanced RR-DTC & Metastatic MTCa
Reference | Kind of PRRT | Number & Kind of Tumor | Cumulative activity (GBq) | Hematologic Toxicity | Gastrointestinal& Hepatobiliary Toxicity | Genitourinary Toxicity | Others | Mortality (Median time to death since the first course of PRRT (months)) |
|---|---|---|---|---|---|---|---|---|
Bertagna F et al. [44] | 90Y-DOTATOC | 1MTC | 9.01 | None | None | None | None | 1 (NA) |
Bodei L et al. [46] | 90Y-DOTATOC | 21MTC | 7.5–19.2 | 15 | NA | None | NA | 4 (NA) |
Bodei L et al. [61] | 90Y-DOTATOC | 4MTC | 3.8_19.2 | None | None | None | None | None |
Czepczynski R et al. [15] | 90Y-DOTATOC | 3FTC, 3HCTC | 3.7_14.8 | 6 | None | 2 | None | 1 (63) |
Gorges R et al. [26] | 90Y-DOTATOC | 1papillary-oxyphilic, 1follicular-oxyphilic, 1Hürthle cell carcinoma | 1.7_9.62 | 3mild Lymphocytopenia | None | None | None | 1 (16) |
Iten F et al. [24] | 90Y-DOTATOC | 17FTC,5PTC, 2No specified | 5.6–30.3 | 3Anemia, 3Transient Thrombocytopenia, 1Transient Leukopenia | 4nausea | 4permanent renal toxicity | None | 11FTC, 4PTC, 2No (13.7) |
Iten F et al. [45] | 90Y-DOTATOC | 31MTC | 74.5 | 3Transient Leukopenia, 1Transient Thrombocytopenia | 5Nausea | 6 | NA | 22 (25.8) |
Versari A et al. [23] | 90Y-DOTATOC | 5PTC, 1Oxiphilic, 3FTC, 2Insular | 4.329_17.95 | 2Transient Anemia, 2Transient Leukopenia | 4nausea, 1transient increase of transaminase | 1permanent renal toxicity | 2Asthenia | None |
Waldherr C et al. [27] | 90Y-DOTATOC | 12MTC, 4PTC, 3FTC | 1.7_14 | 6Anemia, 10Transient Lymphocytopenia | NA | NA | NA | 1 (1) |
Traub-Weidinger T et al. [29] | 90Y-DOTATOC | 1FTC, 1PTC | 7.2_7.4 | None | None | 1renal toxicity | None | 1 (22) |
90Y-DOTA-Lanerotide | 1FTC, 1HCTC | 1.85_3.7 | 2Transient Thrombocytopenia | None | 2 (4_12) | |||
Basu. S et al. [30] | 177Lu-DOTATATE | 8 DTC | 5.5_25.4 | None | None | 1 transient | None | 2 (7_12) |
Beukhof, C et al. [54] | 177Lu-Octreotate | 10MTC | Â | None | 1Diarrhea | None | 1Hemoptysis | 7MTC, 1another cause |
Cinkir, H. Y et al. [31] | 177Lu-DOTATATE | 3MTC, 3PTC, 1FTC | 14.8_44.4 | 2Transient Anemia, 3Transient Leukopenia | None | None | None | 1MTC,2PTC |
Parghane, R. V et al. [50] | 177Lu-DOTATATE | 43MTC | 5.55_33.3 | 1Transient | 1Nausea | None | None | 20 |
Teunissen Jj et al. [12] | 177Lu-DOTATATE | 3HCTC, 1FTC, 1PTC | 22.4–30.1 | NA | NA | NA | NA | 1 (48), 1 (4) |
Vaisman F et al. [52] | 177Lu-DOTATATE | 7MTC | NA | NA | NA | NA | 1transient sexual dysfunction, 2mild hair Loss, 1hypersensitivity dermatologic lesions | 2 (1/7 before the end of the protocol) |
Valkema R et al. [39] | 1111n-Octerotide | 5MTC, 5DTC | NA | None | None | None | None | 4MTC (11.22 (2.76_26.8)), 5DTC (15.8 (13.2_28.2)) |
Stokkel Mp et al. [41] | 111In-DTPA-Octreotide | 6PTC, 5FTC | 14.3_33.1 | 1thrombocytopenia | None | None | None | 1 (5), 2non related (1, 3) |
Budiawan H et al. [6] | 90Y-DOTATATE and 177Lu-DOTATATE | 7MTC, 4FTC, 3HCTC | NA | 8minor hematology, 5Anemia, 1Leukopenia | 6transient increase of transaminase | 5mild renal toxicity | None | 1MTC (12), 2FTC (12), 1HCTC (24) |